MacroGenics' recent royalty deal extends cash runway, but liquidity concerns remain, and further asset sales or dilution may ...

PDUFA date of June 13th 2025 by which FDA will decide upon whether or not UGN-102 should be approved for patients with ...

Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the ...

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

China NMPA approves Akeso's PD-1/CTLA-4 bispecific antibody cadonilimab for first-line treatment of cervical cancer: Hong Kong Friday, June 6, 2025, 12:00 Hrs [IST] Akeso, Inc., a ...

China’s NMPA has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to treat persistent, recurrent or metastatic ...

(RTTNews) - Akeso Inc. announced that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line tr ...

A combination of BRAF and MEK inhibitors plus immunotherapy improved progression-free but not overall survival, compared to dual immune checkpoint blockade.

Lifileucel therapy shows promising long-term survival and response rates in advanced melanoma patients, offering hope for ...

Ongoing trials, like NILE and VOLGA, are investigating PD-1 and CTLA-4 inhibitor combinations for advanced urothelial carcinoma. Future treatment strategies may be influenced by results from these ...

“These Phase 2 data for the combination of vilastobart and atezolizumab demonstrate a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy, together ...